Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Mazdutide peptide icon, one bubble per amino acidMazdutide34 residuesHAQGTFTSDYSKYLDEKKAKEFVEWLLEGGPSSGEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Mazdutide

Beginner tier: 3 mg, weekly · clinical trials

Weight LossResearch
~6-7 days half-life·Injection

Also known as: IBI362, Xinermei, 信诺美

18.55% overall body weight loss at 60 weeks (20.08% in non-diabetic participants), and the curve was still dropping. Mazdutide is a dual GLP-1 and glucagon receptor agonist developed by Innovent Biologics and licensed to Eli Lilly. It earned NMPA approval in China in 2025 for weight management and type 2 diabetes. No Western regulatory path has been announced yet; a US Phase 2 trial (NCT06124807) reported 18.1% weight loss on 16 mg at 32 weeks in 2026. The glucagon component adds thermogenic fat oxidation on top of GLP-1 appetite suppression, targeting both sides of the energy equation. Access outside China is currently limited to grey-market research compounds with no regulatory oversight.

What Is Mazdutide?

20.08% mean body weight loss in non-diabetic participants at 60 weeks, with no plateau in sight. That number comes from GLORY-2 [1], the Phase 3 trial that earned mazdutide its NMPA approval in China.

Mazdutide (IBI362, Xinermei) is an oxyntomodulin analogue that activates two receptors simultaneously. The GLP-1 side suppresses appetite through hypothalamic signaling and slows gastric emptying. The glucagon side drives hepatic fat oxidation and increases resting energy expenditure. Most GLP-1 drugs only cut calories in; mazdutide also increases calories out.

The GLORY-1 trial tested 4 mg and 6 mg doses against placebo in Chinese adults with obesity. The 6 mg arm lost 14.01% of body weight at 48 weeks. GLORY-2 pushed to 9 mg and ran for 60 weeks. A separate head-to-head trial, DREAMS-3, compared mazdutide 6 mg against semaglutide 1 mg in type 2 diabetes. Mazdutide won the combined endpoint of HbA1c below 7% and at least 10% weight loss.

A meta-analysis of 7 randomized controlled trials (n=680) confirmed the metabolic picture: 6.22% body weight reduction and 43.3% triglyceride drop versus placebo [2]. Blood pressure, uric acid, and lipid panels all improved in parallel.

One honest limitation: every completed Phase 3 trial enrolled exclusively Chinese participants. The first US data came from Eli Lilly's Phase 2 trial (NCT06124807, n=179)[4]. At 32 weeks, 16 mg produced 18.1% weight loss vs 0.9% on placebo (efficacy estimand). That trial went up to 16 mg, well above the 9 mg used in GLORY-2. At 16 mg, 20% stopped treatment because of adverse events, mostly gastrointestinal. Western access today means grey-market research compounds with no quality guarantees.

How Mazdutide Works

Mazdutide is an oxyntomodulin analogue, meaning it mimics a gut hormone that naturally activates both GLP-1 and glucagon receptors. That dual signal is what separates it from single-target drugs like semaglutide.

GLP-1 receptor activation does the familiar work. It suppresses appetite through hypothalamic signaling, slows gastric emptying to extend satiety after meals, and promotes glucose-dependent insulin secretion. These are the same pathways semaglutide and liraglutide use.

The glucagon receptor adds a second mechanism. Glucagon activation increases hepatic energy expenditure and shifts the liver toward fat oxidation. This thermogenic effect means mazdutide doesn't just reduce food intake; it also burns more stored fuel at rest. In the GLORY trials, researchers observed concurrent improvements in triglycerides (43.3% reduction in meta-analysis), systolic blood pressure (7.57 mmHg drop), and uric acid alongside weight loss.

Mazdutide's half-life is highly variable. The Phase 1b trial (NCT04440345) measured a range of 6.1 to 28.1 days across subjects. Most clinical protocols use weekly dosing, which works for the majority. But that variability means some individuals may accumulate drug faster or slower than predicted, making the 4-week titration steps more than just a GI tolerance measure.

Mazdutide Benefits

  • Mazdutide benefits center on dual-mechanism weight loss combined with broad cardiometabolic improvement.
  • GLORY-2 Phase 3 [1] showed 18.55% mean weight loss overall at 60 weeks; the non-diabetic subgroup hit 20.08%, and the curve hadn't flattened.
  • Triglycerides dropped 43.3% versus placebo across 7 RCTs (n=680)[2]. That's a lipid reduction few single-target GLP-1 drugs have matched in published meta-analyses.
  • The glucagon component drives thermogenic fat oxidation directly. This is a calorie-out mechanism that GLP-1-only agonists don't provide.
  • DREAMS-3 Phase 3 showed mazdutide 6 mg beat semaglutide 1 mg on the combined endpoint of HbA1c below 7% plus at least 10% weight loss in type 2 diabetes patients.
  • Systolic blood pressure fell 7.57 mmHg and diastolic fell 2.98 mmHg versus baseline in the pooled analysis, improving cardiovascular risk markers alongside weight.
  • No weight-loss plateau was observed at week 60 in GLORY-2. For comparison, semaglutide in STEP-1 plateaued around weeks 60 to 68. The sustained decline may reflect the additional thermogenic contribution from glucagon receptor activation.

Mazdutide: Science vs Community Consensus

Science Only
Scientific Evidence
Strong
Based on 8 key studies·Research only

NMPA-approved (China) dual GLP-1/glucagon agonist with strong Phase 3 data.

Dosing studied: 3–9 mg once weekly SC; titrate 3mg → 6mg → 9mg in 4-week steps
Read the evidence (key study, limitations)

GLORY-2 showed 18.55% overall weight loss (20.08% non-diabetic subgroup) at week 60 with no plateau observed. Head-to-head DREAMS-3 Phase 3 showed superiority over semaglutide 1mg on combined glycemic+weight endpoint in T2D. Meta-analysis of 7 RCTs (n=680) confirms −6.22% body weight and −43.3% triglycerides vs placebo.

Key Study

GLORY-2 Phase 3 (PMID 40421736, NEJM 2025): mazdutide 9mg once weekly, 60 weeks, n=462 (BMI ≥30); −18.55% weight overall, −20.08% non-diabetic subgroup vs −3.02% placebo; no weight-loss plateau at week 60

Limitations

Trial population is exclusively Chinese; no Western (non-Asian) Phase 3 data yet; US Phase 2 under Lilly (NCT06124807, n=179) is published, with its primary endpoint at 32 weeks; half-life highly variable (6.1–28.1 days per Phase 1b); long-term data beyond 60 weeks limited; no head-to-head vs tirzepatide or retatrutide

Community Experience
Weak
3.5/5
Based on <50 Reddit threads (r/peptides) April 2026

Extremely limited Western community experience as of April 2026.

Community dosing: 3–9 mg weekly; some community-adapted sources describe 1.5mg starting dose for cautious Western users
Read the reports (what users report 4, common issues 5)

Compound is China-approved only; grey-market supply is emerging but thin. The small number of Western users who have used it follow the clinical trial titration (3→6→9mg) directly. No independent community protocol consensus has formed.

What users report (4)
  • Strong appetite suppression: dual GLP-1 + glucagon thermogenesis
  • High-concentration 100mg vials require fewer reconstitutions vs smaller-vial GLP-1 peptides
  • Cardiometabolic marker improvements (lipids, BP, uric acid) alongside weight loss
  • No weight-loss plateau observed at 60 weeks in trials
Common issues (5)
  • Not available in any Western pharmacy: China NMPA only, grey-market supply chain required
  • High nausea rates at 9mg during escalation phase
  • Clinical trial population is exclusively Chinese: generalizability to non-Asian populations unconfirmed
  • No FDA submission announced as of October 2026 (Lilly's US trials so far are Phase 1 and 2)
  • Highly variable half-life (6.1–28.1 days) makes PK behavior less predictable than most GLP-1 class drugs
Science-Only Evidence

Western community data is insufficient to establish alignment. The limited community use mirrors GLORY-2 clinical titration (3→6→9mg), reflecting adoption of trial data rather than independent community consensus. No community-originated dosing protocols have emerged.

Mazdutide Dosage Guide

Clinical TrialGLORY-1 Phase 3 Trial: mazdutide in Chinese adults with obesity (NEJM 2025)Source (opens in a new tab)
LevelDose / InjectionFrequency
Beginner3 mg
WeeklyTrack
Moderate6 mg
WeeklyTrack
Aggressive9 mg
WeeklyTrack
Note:

The 100 mg vial format is unusual. Most peptides come in 5 mg or 10 mg vials; mazdutide's high concentration means reconstitution math is less forgiving.

With 2 mL bacteriostatic water in a 100 mg vial, you get 50 mg/mL. That's 5x more concentrated than a typical peptide reconstitution. At that concentration, your doses look like this on a 100-unit insulin syringe: 3 mg = 0.06 mL = 6 units; 6 mg = 0.12 mL = 12 units; 9 mg = 0.18 mL = 18 units.

Double-check your math every time. An accidental 60 units instead of 6 units would deliver 30 mg, ten times the starting dose.

Titration pace matters more than most users expect. The 4-week hold at each dose level isn't just about GI tolerance. It lets the drug reach steady state given that variable 6 to 28 day half-life. Rushing the escalation guarantees worse nausea and unpredictable serum levels.

Store lyophilized powder at 2 to 8 degrees Celsius. After reconstitution, refrigerate and use within 4 weeks. Discard if the solution looks cloudy or you see particles.

Calculate your Mazdutide dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

Mazdutide Protocols by Goal

intermediateClinical Trial60+ weeks (GLORY-2 ran 60 weeks; no defined maximum in current published data)
Titration
Wk 1–4
3 mg (3,000 mcg) · Once weekly · Subcutaneous
Escalation
Wk 5–16
6 mg (6,000 mcg) · Once weekly · Subcutaneous
Maintenance
Wk 17–60+
9 mg (9,000 mcg) · Once weekly · Subcutaneous

Expected: ~12–14% weight loss at 48 weeks (GLORY-1 6mg arm); ~18–20% at 60 weeks (GLORY-2 9mg arm). Lipid, BP, and uric acid improvements concurrent.

Monitor: Weigh weekly. Lab panel at baseline, week 12, week 24, then every 12 weeks: lipids, LFTs, lipase/amylase, HbA1c, CBC, calcitonin. BP and HR at each visit.

How to Inject Mazdutide

  1. 1
    Step 1

    Reconstitute: add 2 mL bacteriostatic water to the 100 mg lyophilized vial. Swirl gently until dissolved. Do not shake. Solution should be clear and colorless.

  2. 2
    Step 2

    Calculate your dose: at 50 mg/mL concentration, 3 mg = 6 units, 6 mg = 12 units, 9 mg = 18 units on a standard 100-unit insulin syringe.

  3. 3
    Step 3

    Draw up the calculated volume using a 29 to 31 gauge insulin syringe. Tap bubbles to the top and push them out before injecting.

  4. 4
    Inject subcutaneously into the abdomen, thigh, or upper arm

    Pinch a fold of skin, insert the needle at a 45 to 90 degree angle, and inject slowly.

  5. 5
    Rotate injection sites with every dose

    Never inject into the same spot twice in a row.

  6. 6
    Step 6

    Timing: once weekly, same day each week, at a consistent time. No strict meal timing requirement.

  7. 7
    Titration schedule: 3 mg weekly for weeks 1 through 4

    Escalate to 6 mg at week 5 if GI effects are tolerable. Hold at 6 mg through week 16 or longer if needed. Escalate to 9 mg at week 17 if 6 mg is well tolerated.

  8. 8
    Step 8

    Store the reconstituted vial upright in the refrigerator at 2 to 8 degrees Celsius. Use within 4 weeks. Do not freeze.

Mixing your own vial? Use the Mazdutide reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

Mazdutide Stacking Protocols

Works With

Avoid

Retatrutide

Triple GLP-1/GIP/glucagon agonist: overlapping GLP-1 and glucagon mechanisms with mazdutide. Additive GI toxicity; no safety or efficacy data for combination. Redundant receptor load with no proven benefit.

Do not combine
Tirzepatide

Dual GLP-1/GIP agonist: overlapping GLP-1 mechanism. High additive GI side effect risk; no safety or efficacy data for combination with mazdutide.

Do not combine
Semaglutide

GLP-1 agonist: same receptor target as mazdutide GLP-1 component. No benefit to combination; high additive nausea and vomiting risk.

Do not combine
Survodutide

Also a GLP-1/glucagon dual agonist: identical mechanism class as mazdutide. Redundant and additive receptor activation; avoid combination.

Do not combine
Sulfonylureas (glipizide, glimepiride, glibenclamide)

Combined glucose-lowering significantly increases hypoglycemia risk. Mazdutide's GLP-1 component potentiates insulin secretion; dose reduction or discontinuation of sulfonylurea required before starting.

Do not combine

Estimated Cost

Brand Price
Xinermei (信诺美): NMPA-approved in China; not exported for Western clinical use. Chinese subsidized/reimbursed pricing not applicable to Western buyers.
Compounded
~$90–$485 per 100mg equivalent (grey-market research compounds, April 2026). Wide range: bulk formats sit near ~$90/100mg equiv, while boxed 10×10mg vials run up to $485. No licensed US compounding pharmacy produces mazdutide.

Pricing updated 2026-04-09

Mazdutide Side Effects

Mazdutide's most common reason for dropout in GLORY-2 was gastrointestinal toxicity at the 9 mg dose during escalation. Nausea, vomiting, and diarrhea are the dominant side effects, and they hit hardest during dose increases.

In GLORY-1, GI adverse events occurred in roughly 50 to 60% of participants at the 6 mg dose. Most were graded mild to moderate. The Phase 1b trial [3] tested 9 mg and 10 mg doses in 36 subjects; GI events were the most frequent adverse reactions at both levels.

Nausea typically peaks in the first 1 to 2 weeks at each new dose tier. Most users report improvement within 2 to 4 weeks of staying at the same dose. If nausea persists past 4 weeks at 6 mg, that's a signal to delay the 9 mg escalation.

Decreased appetite is common and expected. It's part of the GLP-1 mechanism. But severe or prolonged anorexia at any dose warrants clinical attention, particularly in individuals already at lower BMI ranges.

Constipation tends to replace diarrhea at maintenance doses. This shift from loose stools early to constipation later is consistent across the GLP-1 drug class and catches some users off guard.

Heart rate increased by approximately 2.6 beats per minute in the GLORY-1 4 mg and 6 mg arms. That's a small change on average. Persistent tachycardia above 100 bpm should prompt evaluation.

Like all GLP-1 receptor agonists, mazdutide carries a class warning for medullary thyroid carcinoma based on rodent C-cell tumor findings. No calcitonin signal above the 20 ng/L threshold was observed in any GLORY participant. Annual calcitonin monitoring is still recommended.

Pancreatitis is a class risk. Lipase and amylase should be checked at baseline and week 12. Discontinue if levels rise alongside abdominal symptoms. The combination of raised lipase plus persistent abdominal pain is not something to wait out.

Injection site reactions (redness, induration, bruising) occur at standard rates for subcutaneous peptides. Rotating injection sites between abdomen, thigh, and upper arm reduces frequency.

Mazdutide is contraindicated in pregnancy and breastfeeding. Anyone with a personal or family history of medullary thyroid carcinoma or MEN2 should not use it. History of pancreatitis, severe gastroparesis, or known hypersensitivity to mazdutide or its excipients are also exclusions.

If you're taking insulin or sulfonylureas, proactive dose reduction is required before starting. The combined glucose-lowering effect significantly raises hypoglycemia risk. Monitor fasting glucose weekly during the titration phase.

When to stop: less than 5% weight loss by week 16, pancreatitis symptoms, calcitonin elevation with a thyroid nodule, GI effects preventing adequate nutrition, or pregnancy.

Common Issues & Solutions

GI side effects at 6mg or 9mg: hold at the current dose for an additional 4–8 weeks before advancing; anti-nausea agents (ondansetron, ginger supplements) may reduce severity during escalation.

Reconstitution math (100mg vial + 2mL BacWater = 50mg/mL): 3mg = 0.06mL (6 units), 6mg = 0.12mL (12 units), 9mg = 0.18mL (18 units) on a 100-unit insulin syringe. Double-check calculation before each dose: overdose risk at 50mg/mL concentration.

Weight loss stall during escalation: confirm dose escalation is on schedule (3mg → 6mg at week 5, → 9mg at week 17); audit caloric intake: appetite suppression can mask caloric surplus if food quality is poor.

Injection site reactions (redness, induration, bruising): rotate sites every injection; avoid sites with lipohypertrophy; ensure needle is appropriate length for SC (not IM) delivery.

Western product quality uncertainty: mazdutide is not FDA-regulated; an HPLC COA showing ≥98% purity is the usual benchmark; do not use if vial contents appear cloudy, discolored, or particulate is visible after reconstitution.

Ask AI about this page

Ask AI for a second opinion on Mazdutide dosing and side effects

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
  • History of pancreatitis
  • Pregnancy or breastfeeding
  • Known hypersensitivity to mazdutide or any excipients
  • Severe gastrointestinal disease (e.g., gastroparesis)
  • Severe renal impairment (eGFR <15 mL/min): not studied in any GLORY trial; GLP-1 class caution

Drug Interactions

  • Insulin and sulfonylureas: increased hypoglycemia risk due to combined glucose-lowering effects
  • Oral medications may have delayed absorption due to slowed gastric emptying
  • Levothyroxine: monitor thyroid levels as absorption timing may be altered
  • Warfarin: monitor INR more frequently during initiation and dose changes
  • Triple GLP-1/GIP/glucagon agonist: overlapping GLP-1 and glucagon mechanisms with mazdutide. Additive GI toxicity; no safety or efficacy data for combination. Redundant receptor load with no proven benefit.
  • Dual GLP-1/GIP agonist: overlapping GLP-1 mechanism. High additive GI side effect risk; no safety or efficacy data for combination with mazdutide.
  • GLP-1 agonist: same receptor target as mazdutide GLP-1 component. No benefit to combination; high additive nausea and vomiting risk.
  • Also a GLP-1/glucagon dual agonist: identical mechanism class as mazdutide. Redundant and additive receptor activation; avoid combination.

Product Quality

Recommended Monitoring

TestWhenTarget
Body weightWeeklyNot listed
Lipid panel (LDL, HDL, total cholesterol, triglycerides, non-HDL)Baseline, week 12, week 24, every 12 weeks thereafterTriglycerides <150 mg/dL; LDL per cardiovascular risk tier
HbA1c and fasting glucoseBaseline, week 12, week 24, week 48Not listed
Liver enzymes (ALT, AST)Baseline, week 12, week 24ALT/AST <40 U/L (or <3x ULN)
Lipase and amylaseBaseline, week 12, then whenever abdominal symptoms occurLipase <3x ULN; no established threshold: trend + symptoms guide action
Serum calcitoninBaseline, then annually<20 ng/L; refer to endocrinology if elevated
Blood pressure (systolic and diastolic)Each visit during escalation (at least every 4 weeks); every 8–12 weeks at maintenance<130/80 mmHg
Heart rateEach visit60–100 bpm; flag if sustained >100 bpm
Body weight

Primary efficacy measure; drives dose escalation decisions; assess response at weeks 12 and 24

Lipid panel (LDL, HDL, total cholesterol, triglycerides, non-HDL)

Meta-analysis (PMID 38440786): −43.3% triglycerides, −16.8% total cholesterol vs baseline; confirm improvement; flag if triglycerides rising

HbA1c and fasting glucose

Monitor glycemic effect; assess hypoglycemia risk if on concurrent antidiabetics; HbA1c improved ~1.5–2.0pp in T2D trials

Liver enzymes (ALT, AST)

Pancreatitis and hepatic safety surveillance; flag and consider dose hold if ALT/AST >3x ULN

Lipase and amylase

GLP-1 class pancreatitis risk; discontinue if elevated with concurrent abdominal symptoms

Serum calcitonin

GLP-1 class MTC/thyroid C-cell class warning; no calcitonin signal observed in GLORY trials (no subject exceeded 20 ng/L threshold)

Blood pressure (systolic and diastolic)

Meta-analysis: −7.57 mmHg systolic, −2.98 mmHg diastolic vs baseline; antihypertensive medication may require dose reduction

Heart rate

Mild tachycardia (+2.6 bpm) consistently noted in GLORY-1 at both 4mg and 6mg arms; monitor for persistent or symptomatic elevation

Mazdutide Before and After

Weeks 1-4
3mg

Titration initiation. Mild appetite suppression begins. GI side effects (nausea, diarrhea, decreased appetite) are most common in this phase as the body adjusts to dual-receptor activation.

Weeks 5-8
3-6mg

Appetite suppression strengthens. Early weight loss of 3-5% is typical. GI side effects begin to ease for most users as dose escalates to 6mg.

Weeks 9-16
6mg

Steady weight loss continues. Blood glucose and lipid markers start improving. Most users experience 6-10% body weight reduction during this window.

Weeks 17-24
6-9mg

Escalation to full 9mg dose. Weight loss accelerates with the added thermogenic effect of glucagon activation. Phase 3 trials showed ~15% mean body weight loss by week 24.

Weeks 24-48
9mg maintenance

Full dose maintenance. GLORY-2 trial data showed up to 20.1% body weight loss at 48 weeks. Metabolic markers continue improving. Weight loss rate plateaus as a new equilibrium is established.

What to Expect

Weeks 1 to 4 (3 mg, Titration Initiation): Appetite suppression kicks in within days of the first injection. GI effects are most common during this phase, especially nausea and loose stools after the first one or two doses. Don't expect visible weight change yet. The 3 mg dose is below the therapeutic threshold for most people; this phase is about letting your body adjust to dual-receptor activation. Very limited community data exists, but early user reports match the trial findings closely.

Weeks 5 to 16 (6 mg, Escalation Phase): Appetite reduction gets noticeably stronger. The GLORY-1 trajectory puts you on track for roughly 10% weight loss by week 32 at this dose. Blood glucose and lipid markers start improving in this window. Nausea typically eases by weeks 8 to 10. Some users report constipation replacing the early diarrhea, and a mild heart rate bump of about 2.6 bpm was observed in GLORY-1. Insufficient Western community data to confirm these patterns independently.

Weeks 17 to 32 (9 mg, Full Dose, Active Weight Loss): Weight loss accelerates as the glucagon thermogenic contribution ramps up at full dose. GLORY-2 shows a continued linear decline through this window without flattening. Blood pressure, lipid panels, and uric acid continue trending in the right direction. GI effects have largely resolved for most people by this point; constipation is the main remaining complaint. Monitor heart rate and blood pressure through this phase.

Weeks 33 to 60 (9 mg maintenance, Maximum Efficacy Window): GLORY-2 results at week 60: 18.55% overall weight loss, 20.08% in the non-diabetic subgroup. The weight loss trajectory was still declining at the end of the trial. Triglycerides dropped 43.3% and systolic blood pressure fell 7.6 mmHg versus baseline in pooled data. Most users tolerate maintenance well. Annual calcitonin and thyroid monitoring is recommended at this stage.

Detailed Timeline: Science vs Community

Weeks 1–4 (3mg)
Science

Mild appetite suppression onset within days. GI side effects (nausea, diarrhea, decreased appetite) peak in this phase. Minimal weight change: insufficient time at therapeutic dose.

Community

Very limited data. Users consistent with trial reports: appetite suppression begins within days; GI effects noticeable, especially after the first 1–2 injections.

Weeks 5–16 (6mg)
Science

Appetite suppression strengthens. GLORY-1 6mg arm trajectory: ~−10% weight by week 32. Blood glucose and lipid markers begin improving. GI side effects ease for most users after 2–4 weeks at each new dose.

Community

Insufficient community data. Extrapolated from clinical reports: meaningful appetite reduction, early body composition changes, possible constipation replacing early-phase diarrhea.

Weeks 17–32 (9mg)
Science

Weight loss accelerates with glucagon thermogenic contribution added. GLORY-2 trajectory shows continued linear decline through this window. Cardiometabolic markers (BP, lipids, uric acid) continue improving.

Community

No adequate Western community data for this phase.

Weeks 33–60 (9mg maintenance)
Science

GLORY-2: −18.55% overall, −20.08% non-diabetic subgroup at week 60. No plateau observed: weight loss trajectory still declining at week 60. GLORY-1 6mg: −14.01% at week 48. Triglycerides −43.3%, systolic BP −7.6 mmHg vs baseline (meta-analysis).

Community

No adequate Western community data.

Pharmacokinetics

Half-Life
168h
Bioavailability
SC: not yet formally reported
Tmax
24-72 hours
Data Confidence
moderate

Source: Phase 1b trial (NCT04440345), ~7 days

Pharmacokinetics: Active Dose Over Time

t½ = ~6-7 days

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
34
Sequence
HAQGTFTSDYSKYLDEKKAKEFVEWLLEGGPSSG
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers

Who Should Consider Mazdutide

  • Adults with BMI ≥28 (or ≥24 with weight-related comorbidity, per Chinese guidelines)
  • Adults with type 2 diabetes inadequately controlled on metformin
  • Individuals seeking dual-mechanism weight loss beyond GLP-1-only therapy
  • Patients with obesity-related metabolic dysfunction (dyslipidemia, insulin resistance)

Related Peptides

What Changed for Mazdutide

  1. Evidence

    A US Phase 2 trial found 18.1% weight loss on mazdutide 16 mg vs 0.9% on placebo at 32 weeks, published Aug 21, 2026, per Lancet Diabetes Endocrinol.

    What this does not mean: An efficacy-estimand result in 179 adults without diabetes. 16 mg is above the 9 mg top dose on this page and is not a dosing recommendation.

    Source: Lancet Diabetes Endocrinol 2026, Mazdutide in adults with obesity or overweight: US Phase 2 trial (NCT06124807) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

Peptide Schedule Research TeamReviewed Aug 7, 20268 Citations

References

  1. [1]Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight: GLORY-1 Phase 3 (NEJM 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Efficacy and safety of Mazdutide on weight loss: a systematic review and meta-analysis of randomized controlled trials (Nalisa et al., Front Endocrinol 2024) (opens in a new tab)(n=680)PubMed (opens in a new tab)PubMed
  3. [3]Safety and Efficacy of Mazdutide (IBI362) 9mg and 10mg in Chinese Adults: Phase 1b Trial (eClinicalMedicine 2022) (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]Efficacy and safety of mazdutide in adults with obesity or overweight: US multicentre Phase 2 trial (Lancet Diabetes Endocrinol 2026) (opens in a new tab)(n=179)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Refrigerate at 2-8°C
After Reconstitution
Refrigerate, use within 4 weeks
Temperature
2-8°C (36-46°F)

Frequently Asked Questions

No. It's approved by China's NMPA for weight management and T2D as of 2025, but Innovent and Lilly haven't announced an FDA submission. Western availability is limited to grey-market research compounds.

Both include glucagon receptor agonism, but retatrutide is a triple agonist (GLP-1 + GIP + glucagon) while mazdutide is dual (GLP-1 + glucagon only). Retatrutide hit 24.2% weight loss at 48 weeks in Phase 2; mazdutide showed 20.08% at 60 weeks in Phase 3. Direct comparison is tricky given different populations and study designs.

Not at therapeutic doses. The glucagon effect here is primarily hepatic; driving fat oxidation and energy expenditure rather than glycemic spikes. Clinical trials showed no significant hyperglycemia, and HbA1c actually improved in T2D participants. The GLP-1 component also blunts any glucose rise from the glucagon activity.

GLORY-1 evaluated 4mg and 6mg doses selected from Phase 2 data. GLORY-2 evaluated the higher 9mg dose separately. This multi-arm strategy allowed Innovent to file on multiple dose levels with distinct efficacy and safety profiles for each.

Still dropping. GLORY-2 reported no plateau in weight loss at week 60, suggesting continued efficacy with extended treatment. For comparison, semaglutide in STEP-1 plateaued around week 60-68. The 9mg arm appears to still be in its linear phase at 60 weeks; the glucagon-mediated thermogenic component may provide sustained additional weight loss beyond what GLP-1 alone achieves.